Article
Rheumatology
Murat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, Fabian Proft, Mikhail Protopopov, Maryna Verba, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy
Summary: This study aimed to analyze the association between treatment with tumour necrosis factor inhibitors (TNFi) and radiographic spinal progression in patients with axial spondyloarthritis (axSpA). The results showed that TNFi treatment in the current 2-year interval was not associated with retardation of radiographic spinal progression, but TNFi treatment in the previous 2-year interval was significantly associated with a reduction of mSASSS progression.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Adrian Ciurea, Seraphina Kissling, Kristina Buerki, Xenofon Baraliakos, Manouk de Hooge, Monika Hebeisen, Eleftherios Papagiannoulis, Pascale Exer, Rene Bram, Michael J. Nissen, Burkhard Moller, Diego Kyburz, Michael Andor, Oliver Distler, Almut Scherer, Raphael Micheroli
Summary: This study compares disease characteristics and outcomes among patients with axial spondyloarthritis with different levels of sacroiliitis. The results show that patients with bilateral grade 2 sacroiliitis have milder disease and better treatment outcomes compared to those with unilateral/bilateral grade 3-4 sacroiliitis.
Article
Rheumatology
Raphael Micheroli, Seraphina Kissling, Kristina Buerki, Pascale Exer, Rene Braem, Michael J. Nissen, Burkhard Moeller, Michael Andor, Oliver Distler, Almut Scherer, Adrian Ciurea
Summary: The study findings suggest that TNFi can decelerate the radiographic progression of SIJ in patients with axSpA, especially when used for at least 1 year.
Article
Rheumatology
Berkan Armagan, Levent Kilic, Bayram Farisogullari, Gozde Kubra Yardimci, Emre Bilgin, Ertugrul Cagri Bolek, Omer Karadag, Sule Apras Bilgen, Sedat Kiraz, Ihsan Ertenli, Umut Kalyoncu
Summary: This study evaluated the retention rate of secukinumab in r-AxSpA patients and identified predictive factors. The global retention rate of secukinumab was 55% at 12 months. Obesity was found to be associated with a lower risk of secukinumab discontinuation, while multiple TNFi usage increased the risk. This real-life analysis suggests that obesity may not be an adverse risk factor for secukinumab drug retention in r-AxSpA.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Immunology
Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu
Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Celia A. J. Michielsens, Nathan den Broeder, Frank H. J. van den Hoogen, Elien A. M. Mahler, Steven Teerenstra, Desiree van der Heijde, Lise M. Verhoef, Alfons A. den Broeder
Summary: In patients with PsA and axSpA, a T2T TNFi strategy with tapering attempt is non-inferior to a T2T strategy without tapering in terms of the proportion of patients still in low disease activity (LDA) at 12 months, and results in a substantial reduction of TNFi use.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Caroline Ensslin, Raphael Micheroli, Seraphina Kissling, Andrea Gotschi, Kristina Burki, Rene Bram, Manouk de Hooge, Xenofon Baraliakos, Michael J. Nissen, Burkhard Moller, Pascale Exer, Michael Andor, Oliver Distler, Almut Scherer, Adrian Ciurea
Summary: This study investigated sex differences in spinal radiographic progression in axial spondyloarthritis. The results showed that spinal radiographic progression was more severe in men compared to women, with three times higher odds of progression in male patients, and this difference was mediated in part through an increase in baseline radiographic damage.
Review
Rheumatology
Denis Poddubnyy
Summary: This article discusses several challenges related to the concept, diagnosis, and treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in the historical context and in light of recent data. The disease is part of the spectrum of axial spondyloarthritis and is characterized by the absence of definite structural damage in the sacroiliac joints. The introduction of the concept of nr-axSpA has stimulated activities aimed at improving the early diagnosis and treatment of this disease, but it has also raised controversial topics in the field.
Article
Rheumatology
Juergen Braun
Summary: Inflammatory back pain is a common symptom of axial spondyloarthritis caused by inflammation in the axial skeleton. The sacroiliac joints are often affected in early stages, while the spine is affected later on. Both inflammation and structural changes can impact function and mobility. Clinical trials often focus on pain, disease activity, function, mobility, and global health, as well as radiographic progression in the axial skeleton of axSpA patients.
Article
Rheumatology
Marie Vallier, Beatrice Segurens, Elise Larsonneur, Vincent Meyer, Stephanie Ferreira, Christophe Caloustian, Jean-Francois Deleuze, Maxime Dougados, Mathias Chamaillard, Corinne Miceli-Richard
Summary: This study aimed to evaluate the association between gut microbiota composition and patient characteristics, as well as the predictive value on the response to TNF inhibitor treatment in AxSpA patients. The results showed that HLA-B27 status and smoking had a significant influence on gut microbiota composition. In addition, analysis of seven bacterial operational taxonomic units (OTUs) could predict the response to TNFi treatment.
Article
Rheumatology
Walter P. Maksymowych, Robert G. W. Lambert, Liron Caplan, Filip E. van den Bosch, Mikkel ostergaard
Summary: The current RCT design does not fully utilize MRI to select nr-axSpA patients who best demonstrate differences in clinical response rates between active drug and placebo therapies. Future studies should incorporate revised patient inclusion criteria based on expanded MRI evaluation and data-driven definitions of a positive MRI to improve discrimination between therapies.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Review
Immunology
Jin-Xian Huang, Yung-Heng Lee, James Cheng-Chung Wei
Summary: Tumor necrosis factor inhibitors are widely used for axial spondyloarthritis, and current guidelines recommend dose reduction instead of withdrawal. This study reviewed and updated the evidence on dose reduction strategies based on prospective and retrospective studies. The core issues and solutions concerning timing, intensity, maintenance, and monitoring of dose reduction were discussed. Remission/relapse and extra-articular manifestations should be considered in individualized dose reduction plans.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Rheumatology
Hideto Kameda, Shigeto Kobayashi, Naoto Tamura, Yuho Kadono, Kurisu Tada, Masahiro Yamamura, Tetsuya Tomita
Summary: Non-radiographic axial spondyloarthritis (nr-axSpA) is a subgroup of axial spondyloarthritis (axSpA) that does not meet the criteria for ankylosing spondylitis (AS) based on sacroiliac joint radiographs as defined by the modified New York criteria. Although AS and nr-axSpA share similar demographic and clinical features, there are slight differences in sex and inflammatory markers between the two conditions. Japan has recently introduced diagnostic guidelines for nr-axSpA to accommodate their unique healthcare system and low prevalence of HLA-B27 positivity. Additionally, a biological agent targeting interleukin-17 has been approved for nr-axSpA in Japan, with other biologics expected to become available for patients in the near future.
MODERN RHEUMATOLOGY
(2021)
Article
Rheumatology
Adrian Ciurea, Andrea Goetschi, Rene Braem, Kristina Buerki, Pascale Exer, Michael Andor, Michael J. Nissen, Burkhard Moeller, Thomas Huegle, Andrea Rubbert-Roth, Diego Kyburz, Oliver Distler, Almut Scherer, Raphael Micheroli
Summary: This study investigates the definition of early axial spondyloarthritis (axSpA) and the effectiveness of the first tumor necrosis factor inhibitor (TNFi). The results indicate that patients with early axSpA and established axSpA have similar characteristics. TNFi retention and ASAS40 response are comparable between early and established axSpA.
Article
Rheumatology
Ulf Lindstrom, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T. H. Jacobsson, Johan Askling
Summary: Comparing the risk of anterior uveitis (AU) in patients with spondyloarthritis (SpA) treated with secukinumab versus tumor necrosis factor inhibitors (TNFi), it was found that secukinumab appears to be associated with a higher risk of AU compared to monoclonal TNFi, while the risk is similar to etanercept.
ANNALS OF THE RHEUMATIC DISEASES
(2021)